Mitoxantrone

Mitoxantrone

SCHEMBL3928

Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TOP2A

The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A known ✓ P11388 2/20 0.97
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
MAPK1 P28482 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
LMNA P02545 3/20 1.00
BLM P54132 3/20 1.00
USP2 O75604 3/20 1.00
TP53 P04637 3/20 1.00
RECQL P46063 3/20 1.00
MAPT P10636 3/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
POLB P06746 2/20 1.00
KDM4E B2RXH2 2/20 1.00
ALDH1A1 P00352 2/20 1.00
APEX1 P27695 2/20 1.00
GMNN O75496 1/20 1.00
PIM1 P11309 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitoxantrone SCHEMBL29462659 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Hydrochloric Acid SCHEMBL11305688 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Mitoxantrone SCHEMBL29366412 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Hydrochloric Acid SCHEMBL10522176 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Mitoxantrone SCHEMBL1256885 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Hydrochloric Acid SCHEMBL11039686 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Mitoxantrone SCHEMBL532914 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Mitoxantrone SCHEMBL66384 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Mitoxantrone SCHEMBL2342900 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA
Hydrochloric Acid SCHEMBL11278695 1.00 MEN1 (1.00) MEN1KMT2AMAPK1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 71133 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
US-20260137707-A1 METHODS OF MODULATING ATXN2 EXPRESSION UNIV OF UTAH RESEARCH FOUNDATION (US) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260132141-A1 PROTEIN PHOSPHATASE 2A ACTIVATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-14 US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2026-04-23 US claimed
US-20260108478-A1 USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2026-04-23 US claimed
WO-1993016733-A1 TOPICAL COMPOSITION CONTAINING HYALURONIC ACID AND NSAIDS NORPHARMCO INC. (CA) 1993-09-02 WO claimed
EP-0345251-B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS FIDIA S.p.A. (IT) 1992-11-11 EP claimed
EP-0251298-B1 USE OF EXOGENOUS GANGLIOSIDES FOR THE PREPARATION OF A MEDICAMENT FOR USE IN TUMORAL DISEASES AS A PROTECTIVE FACTOR AGAINST TOXICITY BY ANTITUMOR DRUGS FIDIA S.p.A. (IT) 1991-11-13 EP claimed
EP-0445255-A1 TREATMENT OF CONDITIONS AND DISEASE. NORPHARMCO INC (CA) 1991-09-11 EP claimed
CN-1051503-A Disease and treatment of diseases NORPHARMCO INC (CA) 1991-05-22 CN claimed
WO-1991004058-A2 TREATMENT OF CONDITIONS AND DISEASE NORPHARMCO INC. (CA) 1991-04-04 WO claimed
EP-0236822-B1 STABLE INJECTABLE PHARMACEUTICAL FORMULATION FOR 1,4-DIHYDROXY-5,8-BIS((2-(HYDROXYETHYLAMINO)-ETHYL)AMINO)ANTHRAQUINONE, DIHYDROCHLORIDE AMERICAN CYANAMID COMPANY (US) 1990-12-27 EP claimed
EP-0345251-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS. WINDLESHAW ENTERPRISES LTD (GB) 1989-12-13 EP claimed
WO-1988001171-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS WINDLESHAW ENTERPRISES LIMITED (GB) 1988-02-25 WO claimed
EP-0251298-A2 Use of exogenous gangliosides for the preparation of a medicament for use in tumoral diseases as a protective factor against toxicity by antitumor drugs FIDIA S.p.A. (IT) 1988-01-07 EP claimed